Postprandial plasma glucose concentrations and insulin responses were significantly reduced when overweight adults were given bread containing 60% RS (Yamada et al
Cagrilintide is a long-acting amylin receptor agonist currently being investigated for its effects on appetite regulation, energy balance, and metabolic health
However, clinical evidence suggests this effect is generally modest for most medications when appropriate timing intervals are observed
In this context, it has been demonstrated that treatments with either a GLP1/Estrogen (GLP1/E) conjugate, a unimolecular GLP1/GIP (gastric inhibitory peptide) dual agonist, or a GLP1/GIP/Glucagon triagonist, markedly reduced body weight and improved diabetic complications, including hyperinsulinemia, in preclinical models of obesity in males 33,34,35